You are here


Preventive Technologies Agreement (PTA)

  • Bangladesh
  • Botswana
  • Ethiopia
  • Jamaica
  • Kenya
  • Malawi
  • Mozambique
  • Rwanda
  • South Africa
  • Tanzania
  • Uganda
  • United States
  • Zambia
  • Zimbabwe
2009 - 2014

To help develop selected HIV prevention technologies and strategies to advance the global HIV prevention and health agenda, the U.S. Agency for International Development (USAID) awarded FHI 360 the five-year Preventive Technologies Agreement (PTA) (2009–2014). Under PTA, FHI 360 and its partners achieved these goals by generating knowledge about biomedical, behavioral and programmatic solutions to HIV and providing scientific support and technical assistance to governments and nongovernmental organizations in 15 countries.

FHI 360 developed and introduced innovative HIV prevention technologies — including microbicides and antiretrovirals — and worked with local partners to address the need for HIV prevention options, particularly for women.

This work supported USAID’s HIV prevention agenda by focusing on women, girls, gender equality and capacity building to enable countries to refine their responses to HIV and other health challenges, ultimately advancing the science of HIV prevention.

The PTA end-of-project report summarizes these achievements. The interactive version offers video interviews from those who worked on the project, as well as links to journal article abstracts, briefs, reports and tools produced under the project. A print version is also available.

Technical areas
CAPRISA 004 study
FEM-PrEP trial
Project highlights
Project resources
Project newsletters


  • HIV prevention clinical trials
  • Support for HIV prevention research
  • Microbicide implementation
  • Other social behavioral evidence
  • Family planning and HIV integration
  • Support for field activities
  • Product quality and compliance (PQC)


PTA supported this landmark study, which was the first to show that use of a microbicide gel can reduce a woman’s risk of acquiring HIV.


This multi-country clinical trial of daily use of an oral antiretroviral drug to prevent HIV, funded by the PTA, highlighted the need for greater attention to understanding adherence to HIV pre-exposure prophylaxis among women at high risk of HIV infection.


PTA’s accomplishments include:

  • Building the capacity of seven new centers in five countries to conduct high-quality HIV-prevention research
  • Addressing gender-related barriers that could interfere with women’s access to and use of microbicides
  • Assisting in-country research partners and providing training in protocol design, data management, study monitoring and data analysis
  • Developing and disseminating evidence-based tools for preventing the spread of HIV among young people, including “positive prevention” among youth who are already living with HIV
  • Designing, testing and adapting strategies to integrate family planning and HIV-prevention services
  • Monitoring the quality of medical devices, pharmaceuticals and other commodities provided by USAID to programs around the world



View all resources